{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-051106","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2022-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.491430+00:00","generated_at":"2026-06-27T04:44:07.619713+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Agios Q4 net loss $98.6M; FDA approved PYRUKYND for PK deficiency; cash $1.3B","bullets":["Net loss $98.6M in Q4 2021 vs $84.5M in Q4 2020; full-year net loss $356.5M.","Received FDA approval for PYRUKYND (mitapivat), first therapy for hemolytic anemia in adults with PK deficiency.","Cash, cash equivalents and marketable securities $1.3B as of Dec. 31, 2021; expects to fund operations to cash-flow positivity.","Dosed first patients in three pivotal trials of PYRUKYND in thalassemia and sickle cell disease.","R&D expenses $73.3M in Q4 2021, up from $59.4M in Q4 2020 due to pivotal study start-up costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-051106","json":"https://secwatch.observer/filing/0001193125-22-051106.json","markdown":"https://secwatch.observer/filing/0001193125-22-051106.md","text":"https://secwatch.observer/filing/0001193125-22-051106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000119312522051106/0001193125-22-051106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000119312522051106/d252010d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T04:44:07.619713+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}